Differentially imprinted innate immunity by mucosal boost vaccination determines antituberculosis immune protective outcomes, independent of T-cell immunity

Mucosal Immunology

Volumn 6, Issue 3, 2013, Pages 612-625

  Jeyanathan, M ^a,b   Damjanovic, D ^a,b   Shaler, C R ^a,b   Lai, R ^a,b   Wortzman, M ^a,b   Yin, C ^a,b   Zganiacz, A ^a,b   Lichty, B D ^a,b   Xing, Z ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; BETA INTERFERON; CD8 ANTIGEN; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; NITRIC OXIDE; TUBERCULOSTATIC AGENT; VIRUS VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CELL PHAGOCYTOSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; INNATE IMMUNITY; LUNG TUBERCULOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VESICULAR STOMATITIS VIRUS;

EID: 84876377212     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2012.103     Document Type: Article

References (55)

1. McShane, H. Prime-boost immunization strategies for infectious diseases. Curr. Opin. Mol. Ther. 4, 23-27 (2002).
2. Nolz, J.C. & Harty, J.T. Strategies and implications for prime-boost vaccination to generate memory CD8 T cells. Adv. Exp. Med. Biol. 780, 69-83 (2011).
3. Woodland, D.L. Jump-starting the immune system: prime-boostingcomes of age. Trends Immunol. 25, 98-104 (2004).
4. Draper, S.J. & Heeney, J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62-73 (2010).
5. Rollier, C.S., Reyes-Sandoval, A., Cottingham, M.G., Ewer, K. & Hill, A.V. Viral vectors as vaccine platforms: deployment in sight. Curr. Opin. Immunol. 23, 377-382 (2011).
6. Xing, Z. et al. Recent advances in the development of adenovirus-and poxvirus-vectored tuberculosis vaccines. Curr. Gene Ther. 5, 485-492 (2005).
7. Radosevic, K., Rodriguez, A., Lemckert, A. & Goudsmit, J. Heterologous prime-boost vaccinations for poverty-related diseases: advantages and future prospects. Expert Rev. Vaccines 8, 577-592 (2009).
8. Paris, R.M., Kim, J.H., Robb, M.L. & Michael, N.L. Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1. Expert Rev. Vaccines 9, 1055-1069 (2010).
9. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 11 (Suppl), S45-S53 (2005).
10. Ranasinghe, C. & Ramshaw, I.A. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert Rev. Vaccines 8, 1171-1181 (2009).
11. Belyakov, I.M. & Ahlers, J.D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J. Immunol. 183, 6883-6892 (2009).
12. Belyakov, I.M., Moss, B., Strober, W. & Berzofsky, J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. USA 96, 4512-4517 (1999).
13. Croyle, M.A. et al. Nasal deliveryofanadenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3, e35482008.
14. Cooper, A.M. T cells in mycobacterial infection and disease. Curr. Opin. Immunol. 21, 378-384 (2009).
15. Jeyanathan, M., Heriazon, A. & Xing, Z. Airway luminal Tcells: a newcomer on the stage of TB vaccination strategies. Trends Immunol. 31, 247-252 (2010).
16. Seder, R.A., Darrah, P.A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247-258 (2008).
17. Urdahl, K.B., Shafiani, S. & Ernst, J.D. Initiation and regulation of T-cell responses in tuberculosis. Mucosal Immunol. 4, 288-293 (2011).
18. Barker, L.F., Brennan, M.J., Rosenstein, P.K. & Sadoff, J.C. Tuberculosis vaccine research: the impact of immunology. Curr. Opin. Immunol. 21, 331-338 (2009).
19. Hanekom, W.A. et al. Immunological outcomes of new tuberculosis vaccine trials: WHO panel recommendations. PLoS Med. 5, e1452008).
20. Ottenhoff, T.H. et al. First in humans: a new molecularly defined vaccine shows excellent safety and strong induction of long-lived Mycobacterium tuberculosis-specific Th1-cell like responses. Hum. Vaccine 6, 1007-1015 (2010).
21. Antonelli, L.R. et al. Intranasal poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010).
22. Potian, J.A., Rafi, W., Bhatt, K., McBride, A., Gause, W.C. & Salgame, P. Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway. J. Exp. Med. 208, 1863-1874 (2011).
23. Shaler, C.R., Horvath, C., Lai, R. & Xing, Z. Understanding delayed T-cell priming, lung recruitment, and airway luminal T-cell responses in host defense against pulmonary tuberculosis. Clin. Dev. Immunol. 2012, 628293 (2012).
24. Zganiacz, A. et al. TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J. Clin. Invest. 113, 401-413 (2004).
25. Neutra, M.R. & Kozlowski, P.A. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6, 148-158 (2006).
26. Barouch, D.H. et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J. Immunol. 172, 6290-6297 (2004).
27. Casimiro, D.R. et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol. 77, 6305-6313 (2003).
28. Shiver, J.W.et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335 (2002).
29. Santosuosso, M., Zhang, X., McCormick, S., Wang, J., Hitt, M. & Xing, Z. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 Tcells within the airway lumen. J. Immunol. 174, 7986-7994 (2005).
30. Roediger, E.K., Kugathasan, K., Zhang, X., Lichty, B.D. & Xing, Z. Heterologous boostingofrecombinant adenoviral prime immunization with a novel vesicular stomatitis virus-vectored tuberculosis vaccine. Mol. Ther. 16, 1161-1169 (2008).
31. Fremond, C.M., Yeremeev, V., Nicolle, D.M., Jacobs, M., Quesniaux, V.F. & Ryffel, B. Fatal Mycobacterium tuberculosis infection despite adaptive immune response in the absence of MyD88. J. Clin. Invest. 114, 1790-1799 (2004).
32. Cooper, A.M., Mayer-Barber, K.D. & Sher, A. Role of innate cytokines in mycobacterial infection. Mucosal Immunol. 4, 252-260 (2011).
33. Wang, J., Wakeham, J., Harkness, R. & Xing, Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Invest. 103, 1023-1029 (1999).
34. Xing, Z., Zganiacz, A. & Santosuosso, M. Role of IL-12 in macrophage activation during intracellular infection: IL-12 and mycobacteria synergis-tically release TNF-alpha and nitric oxide from macrophages via IFN-gamma induction. J. Leukoc. Biol. 68, 897-902 (2000).
35. Redford, P.S., Murray, P.J. & O'Garra, A. The role of IL-10 in immune regulation during M. tuberculosis infection. Mucosal Immunol. 4, 261-270 (2011).
36. McCormick, S., Shaler, C.R. & Xing, Z. Pulmonary mucosal dendritic cells in T-cell activation: implications for TB therapy. Expert Rev. Respir. Med. 5, 75-85 (2011).
37. Cooper, A.M., Roberts, A.D., Rhoades, E.R., Callahan, J.E., Getzy, D.M. & Orme, I.M. The role of interleukin-12 in acquired immunity to Mycobacter-ium tuberculosis infection. Immunology 84, 423-432 (1995).
38. Byrnes, A.A. et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. Eur. J. Immunol. 31, 2026-2034 (2001).
39. Cousens, L.P., Orange, J.S., Su, H.C. & Biron, C.A. Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection. Proc. Natl. Acad. Sci. USA 94, 634-639 (1997).
40. Rayamajhi, M., Humann, J., Penheiter, K., Andreasen, K. & Lenz, L.L. Induction of IFN-alphabeta enables Listeria monocytogenes to suppress macrophage activation byIFN-gamma. J. Exp. Med. 207, 327-337 (2010).
41. Xing, Z. & Lichty, B.D. Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis (Edinb) 86, 211-217 (2006).
42. Yan, B.S. et al. Progression of pulmonary tuberculosis and efficiency of bacillus Calmette-Guerin vaccination are genetically controlled via a common sst1-mediated mechanism of innate immunity. J. Immunol. 179, 6919-6932 (2007).
43. Beveridge, N.E. et al. A comparisonof IFNgamma detection methods used in tuberculosis vaccine trials. Tuberculosis (Edinb) 88, 631-640 (2008).
44. Goulding, J. et al. Respiratory infections: do we ever recover?. Proc. Am. Thorac. Soc. 4, 618-625 (2007).
45. Sui, Y. et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc. Natl. Acad. Sci. USA 107, 9843-9848 (2010).
46. Wang, J. et al. Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J. Immunol. 173, 6357-6365 (2004).
47. Leemans, J.C. et al. Macrophages play a dual role during pulmonary tuberculosis in mice. J. Infect. Dis. 191, 65-74 (2005).
48. Sun, J.C. & Lanier, L.L. Versatility in NK cell memory. Immunol. Cell. Biol. 89, 327-329 (2011).
49. Manca, C. et al. Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-alpha/beta. Proc. Natl. Acad. Sci. USA 98, 5752-5757 (2001).
50. Manca, C. et al. Hypervirulent M. tuberculosis W/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res. 25, 694-701 (2005).
51. Cousens, L.P. et al. Two roads diverged: interferon alpha/beta-and interleukin 12-mediated pathways in promoting T cell interferon gamma responses during viral infection. J. Exp. Med. 189, 1315-1328 (1999).
52. Santosuosso, M. et al. Mucosal luminal manipulation of T cell geography switches on protective efficacy by otherwise ineffective parenteral genetic immunization. J. Immunol. 178, 2387-2395 (2007).
53. Santosuosso, M., McCormick, S., Zhang, X., Zganiacz, A. & Xing, Z. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect. Immun. 74, 4634-4643 (2006).
54. + antigen presenting cells from the alveolar space, lung parenchyma and spleen differ in their phenotype and capabilities to activate naive and antigen-primed T cells. BMC Immunol. 9, 48 (2008).
55. Santosuosso, M., McCormick, S. & Xing, Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol. 18, 283-291 (2005).